Published in PLoS One on July 31, 2015
Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget (2016) 1.44
Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation. Am J Cancer Res (2015) 0.83
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology (2016) 0.79
Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS One (2015) 0.75
Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. PLoS One (2016) 0.75
Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing. Transl Androl Urol (2016) 0.75
Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. Sci Rep (2017) 0.75
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Proteomics. Tissue-based map of the human proteome. Science (2015) 10.21
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell (2014) 5.52
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol (2003) 3.21
Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med (1993) 3.00
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
A molecular taxonomy for urothelial carcinoma. Clin Cancer Res (2012) 2.37
Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol (2009) 2.36
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol (2015) 2.32
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov (2014) 2.09
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res (2010) 1.99
Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology (2013) 1.71
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res (2005) 1.66
Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol (2003) 1.62
Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One (2012) 1.56
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res (2012) 1.51
Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev (2005) 1.50
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol (2010) 1.49
Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res (2009) 1.44
Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol (2013) 1.28
Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol (2013) 1.03
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol (2014) 0.99
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol (2015) 0.91
Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling. Exp Ther Med (2010) 0.80
Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer. Aktuelle Urol (2010) 0.80
DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res (2008) 1.41
N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res (2006) 1.36
Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res (2004) 1.32
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30
Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.30
Aquaporin expression in human lymphocytes and dendritic cells. Am J Hematol (2004) 1.17
CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med (2004) 1.14
An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res (2011) 1.13
Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiol Biomarkers Prev (2009) 1.07
Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res (2009) 1.06
DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res (2011) 0.98
Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle (2008) 0.95
Epigenomics and ovarian carcinoma. Biomark Med (2010) 0.91
Forced cytochrome B gene mutation expression induces mitochondrial proliferation and prevents apoptosis in human uroepithelial SV-HUC-1 cells. Int J Cancer (2009) 0.91
Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun (2007) 0.88
OGDHL is a modifier of AKT-dependent signaling and NF-κB function. PLoS One (2012) 0.87
SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. J Mol Med (Berl) (2012) 0.85
A single nucleotide polymorphism in the human PIGK gene associates with low PIGK expression in colorectal cancer patients. Int J Oncol (2012) 0.75
Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS One (2015) 0.75